Neuromyelitis optica is an uncommon disease affecting the central nervous system, spinal cord and optic nerves. The major symptoms of neuromyelitis optica are inflammation of eye called optic neuritis followed by inflammation of spinal cord called transverse myelitis.
The inflammation mostly occurs in one eye but both the eyes can be eventually affected. This is followed by loss of clear vision. During early stages it might be difficult to distinguish between neuromyelitis optica and multiple sclerosis as both involve optic neuritis and myelitis as symptoms. However, the symptoms tend to be more severe in case of neuromyelitis optica. Neuromyelitis optica is be considered autoimmune disease with no known exact cause of autoimmunity.
COVID-19 impact has been unprecedented on various sectors of economy. The international neuromyelitis optica market will not remain untouched from its impact. The supply chain disruptions, volatility in markets, uncertainty in lockdown regulations could be some of the areas where the global neuromyelitis optica market can witness COVID-19 consequences.
The factors that would drive the growth of the global neuromyelitis optica market are growing incidence of the disorder. The growing awareness among the governments towards orphan drugs and diseases is also expected to drive the global neuromyelitis optica market upwards.
Recent drug developments and approvals by FDA to the drugs for the treatment of neuromyelitis optica will further encourage the industry and future investments can be expected to push the global neuromyelitis optica market for growth. Developing appropriate diagnostics to differentiate the neuromyelitis optica from multiple sclerosis can further boost the global neuromyelitis optica market.
Product pipeline of many companies involving drugs for improving symptoms avoiding relapses and restoring the neurological functioning of the patients will also add to the growth of the market of neuromyelitis optica. Long trial periods together with stringent regulatory reforms could be one major reasons for the growth hindrance of the neuromyelitis optica market.
The Global market of neuromyelitis optica is expected to grow at a steady rate owing to the growing incidence of neuromyelitis optica syndrome in the world. Based on the drug class monoclonal antibody can be estimated to register a steady growth owing to the recent FDA approval it got for the treatment of neuromyelitis optica.
Based on the route of administration subcutaneous segment can be poised to mark a decent growth in the global neuromyelitis optica market as the dosage can be taken as per the patient’s convenience. Based on the distribution channel hospital pharmacies can be expected to be attractive as the medication will be under the medical guidance.
North America can be estimated to dominate the global market for neuromyelitis optica owing to the accessibility of drug and other complementary treatment to the people coupled with greater awareness among the medics to diagnose the disorder.
East Asia can be estimated to contribute positively to the emerging market of neuromyelitis optica since the incidence rates are higher in East Asians at 3.5 per 100000. Europe can also be expected to contribute to the growing market of neuromyelitis optica as there are increased incidence cases in Denmark Sweden and Hungary.
Oceania can also be estimated to grow as an emerging market for the global neuromyelitis optica market as both Australia and New Zealand have higher incidences coupled with adequate medical facilities.
The global neuromyelitis optica market is segmented based on drug class/therapy type, indication type, route of administration, distribution channel and region.
Drug Class :
Indication Type :
Route of Administration :
Distribution Channel :
Explore Similar Insights
Neuromyelitis Optica Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
Chat With
MaRIA
